| 霍奇金淋巴瘤的治疗共识及临床研究进展 |
| |
| 引用本文： | 闵琦,王华庆. 霍奇金淋巴瘤的治疗共识及临床研究进展[J]. 白血病．淋巴瘤, 2014, 23(10): 581-582 |
| |
| 作者姓名： | 闵琦 王华庆 |
| |
| 作者单位： | 300060,天津医科大学肿瘤医院淋巴瘤科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室 |
| |
| 摘 要： | 霍奇金淋巴瘤（HL）起源于淋巴造血组织,是治疗效果较好、治愈率较高的恶性肿瘤之一.目前,早期HL可通过化疗联合受累野放疗或单纯化疗的方式治愈,但复发、难治性HL患者仍缺乏有效治疗手段.近年来随着个体化分层治疗、靶向药物brentuximab vedotin、PET-CT检查等新型策略的应用,HL的预后评价及治疗研究均取得了新进展.
|
| 关 键 词： | 霍奇金淋巴瘤 预后 治疗 |
Treatment strategies and clinical research progress of Hodgkin lymphoma |
| |
| Min Qi,Wang Huaqing. Treatment strategies and clinical research progress of Hodgkin lymphoma[J]. Journal of Leukemia & Lymphoma, 2014, 23(10): 581-582 |
| |
| Authors: | Min Qi Wang Huaqing |
| |
| Affiliation: | (Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China) |
| |
| Abstract: | Hodgkin lymphoma （HL） originates from the lymphoid hematopoietic tissues and has a good treatment outcome with relatively high cure rate.Early stage HL is curable with abbreviated chemotherapy plus involved-filed radiotherapy or chemotherapy alone.However,patients with refractory or relapsed disease still lack effective treatment.In recent years,with the application of risk stratified treatment,novel drugs such as brentuximad vedotin,and PET-CT evaluation,significant progress has been made in prognosis and treatment of HL |
| |
| Keywords: | Hodgkin lymphoma Prognosis Treatment |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
